JP2022529929A5 - - Google Patents
Info
- Publication number
- JP2022529929A5 JP2022529929A5 JP2021561599A JP2021561599A JP2022529929A5 JP 2022529929 A5 JP2022529929 A5 JP 2022529929A5 JP 2021561599 A JP2021561599 A JP 2021561599A JP 2021561599 A JP2021561599 A JP 2021561599A JP 2022529929 A5 JP2022529929 A5 JP 2022529929A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- humanized anti
- seq
- patient
- domain described
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025122188A JP2025169256A (ja) | 2019-04-17 | 2025-07-22 | α4β7阻害薬及びIL-23阻害薬の併用療法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962835349P | 2019-04-17 | 2019-04-17 | |
| US62/835,349 | 2019-04-17 | ||
| PCT/US2020/028861 WO2020215019A1 (en) | 2019-04-17 | 2020-04-17 | Alpha4beta7 inhibitor and il-23 inhibitor combination therapy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025122188A Division JP2025169256A (ja) | 2019-04-17 | 2025-07-22 | α4β7阻害薬及びIL-23阻害薬の併用療法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022529929A JP2022529929A (ja) | 2022-06-27 |
| JP2022529929A5 true JP2022529929A5 (cg-RX-API-DMAC7.html) | 2023-04-25 |
| JP7778567B2 JP7778567B2 (ja) | 2025-12-02 |
Family
ID=72837950
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021561599A Active JP7778567B2 (ja) | 2019-04-17 | 2020-04-17 | α4β7阻害薬及びIL-23阻害薬の併用療法 |
| JP2025122188A Pending JP2025169256A (ja) | 2019-04-17 | 2025-07-22 | α4β7阻害薬及びIL-23阻害薬の併用療法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025122188A Pending JP2025169256A (ja) | 2019-04-17 | 2025-07-22 | α4β7阻害薬及びIL-23阻害薬の併用療法 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20230096620A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3956358A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7778567B2 (cg-RX-API-DMAC7.html) |
| MA (1) | MA55735A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020215019A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20240103043A (ko) * | 2021-11-23 | 2024-07-03 | 얀센 바이오테크 인코포레이티드 | 항-il23 특이적 항체로 궤양성 결장염을 치료하는 방법 |
| EP4720125A1 (en) | 2023-05-30 | 2026-04-08 | Paragon Therapeutics, Inc. | Alpha4beta7 integrin antibody compositions and methods of use |
| EP4762093A1 (en) | 2023-08-14 | 2026-06-24 | Paragon Therapeutics, Inc. | Alpha 4 beta 7 integrin binding proteins and methods of use |
| WO2026058045A1 (en) * | 2024-09-12 | 2026-03-19 | Takeda Pharmaceutical Company Limited | Alpha4beta7 inhibitor and il-23 inhibitor combination therapy |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7147851B1 (en) * | 1996-08-15 | 2006-12-12 | Millennium Pharmaceuticals, Inc. | Humanized immunoglobulin reactive with α4β7 integrin |
| EP2352762A1 (en) * | 2008-11-03 | 2011-08-10 | Schering Corporation | Inflammatory bowel disease biomarkers and related methods of treatment |
| UY34054A (es) * | 2011-05-02 | 2012-11-30 | Millennium Pharm Inc | FORMULACIÓN PARA ANTICUERPO ANTI-a(alfa)4B(Beta)7 |
| UA116189C2 (uk) * | 2011-05-02 | 2018-02-26 | Мілленніум Фармасьютікалз, Інк. | КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА |
| MA41636A (fr) * | 2015-03-06 | 2018-01-09 | Millennium Pharm Inc | Méthode de traitement de la cholangite sclérosante primitive |
| EP3277719B1 (en) * | 2015-03-31 | 2022-03-16 | Sorriso Pharmaceuticals, Inc. | Polypeptides |
| MX2018003376A (es) * | 2015-09-17 | 2018-08-15 | Amgen Inc | Prediccion de la respuesta clinica a antagonistas de il23 mediante el uso de biomarcadores de la via de il23. |
| WO2017106595A1 (en) * | 2015-12-18 | 2017-06-22 | Sciadonics, Inc. | Lipid formulations containing bioactive fatty acids and a non-fatty acid anti-inflammatory agent |
| JP7162533B2 (ja) * | 2016-05-04 | 2022-10-28 | ミレニアム ファーマシューティカルズ, インコーポレイテッド | 炎症性腸疾患の治療を目的とする三剤併用療法 |
| CN116712540A (zh) * | 2016-12-14 | 2023-09-08 | 比奥拉治疗股份有限公司 | 使用整联蛋白抑制剂治疗胃肠道疾病 |
| EP3601350A1 (en) * | 2017-03-27 | 2020-02-05 | Boehringer Ingelheim International GmbH | Anti il-36r antibodies combination therapy |
| IL270201B2 (en) * | 2017-04-28 | 2026-05-01 | Millennium Pharm Inc | A method for treating childhood disorders |
| EP3810085A1 (en) * | 2018-06-20 | 2021-04-28 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an integrin inhibitor |
-
2020
- 2020-04-17 US US17/604,324 patent/US20230096620A1/en active Pending
- 2020-04-17 WO PCT/US2020/028861 patent/WO2020215019A1/en not_active Ceased
- 2020-04-17 EP EP20792259.2A patent/EP3956358A4/en active Pending
- 2020-04-17 MA MA055735A patent/MA55735A/fr unknown
- 2020-04-17 JP JP2021561599A patent/JP7778567B2/ja active Active
-
2025
- 2025-07-22 JP JP2025122188A patent/JP2025169256A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7579227B2 (ja) | 瘻孔を伴うクローン病の治療用ベドリズマブ | |
| JP7119114B2 (ja) | 潰瘍性大腸炎を治療する方法 | |
| CN112689512B (zh) | 用于治疗银屑病的组合物和方法 | |
| JP2022188083A (ja) | 化膿性汗腺炎の処置 | |
| WO2022075476A1 (en) | Method for treating ox40 related disease | |
| JP2024069230A5 (cg-RX-API-DMAC7.html) | ||
| JP2022523530A (ja) | 化膿性汗腺炎の治療のための抗IL-α抗体 | |
| JP2023522196A (ja) | 化膿性汗腺炎の治療 | |
| JP2022529266A (ja) | 乾癬性関節炎に罹患している対象者の治療方法 | |
| JP7093940B2 (ja) | 全身性強皮症治療用医薬組成物 | |
| JP7297930B2 (ja) | クローン病を治療する方法に使用するためのミリキズマブ | |
| CN120204387A (zh) | 治疗银屑病的方法 | |
| JP2024517796A (ja) | 抗baffr抗体を使用するループス腎炎の治療 | |
| JP7863690B2 (ja) | 潰瘍性大腸炎を治療する方法 | |
| JP2020517648A5 (cg-RX-API-DMAC7.html) | ||
| EP3952993B1 (en) | Method of treating fumaric acid ester-resistant plaque psoriasis | |
| WO2024077113A1 (en) | Methods of treating fatigue in ulcerative colitis | |
| WO2026060205A1 (en) | PAN-ELR+ CXC CHEMOKINE ANTIBODIES AND IL-23p19 ANTIBODIES FOR THE TREATMENT OF ULCERATIVE COLITIS | |
| CN121889429A (zh) | 用于治疗嗜酸性肉芽肿性多血管炎的IL-5R-α抗体 | |
| JP2024516019A (ja) | 抗baffr抗体を使用する全身性エリテマトーデスのための治療 | |
| WO2025257781A1 (en) | Treatment of systemic sclerosis using anti-baff-r antibodies | |
| HK40052952B (en) | Compositions and methods for treatment of psoriasis | |
| HK40052952A (en) | Compositions and methods for treatment of psoriasis | |
| Swendrowski | Ustekinumab: a review of the effectiveness of targeting interleukin-12/23P40 in psoriasis and other immune-mediated diseases | |
| CN116829582A (zh) | 安全施用抗Tau抗体的方法 |